The Icos Alumni: Where Are They Now?
Luke Timmerman11/18/09Comments (4)Follow @ldtimmerman
(Page 5 of 9)
—Dan Herendeen, research scientist, Tumor Vaccine Group, University of Washington
—Carmen Hertel, research associate, Unigen
—Jeff Hesselberg, vice president of regulatory affairs, GTx
—John Hill, director of medical sciences, Amgen
—Mark Hill, senior scientist in autoimmunity, ZymoGenetics
—Stephen Hill, executive director of manufacturing, Amgen
—Jim Hnilo, project manager, Ricerca Biosciences [Added: 10:10 am, 6/11/10]
—Nicole Hoagland, clinical study manager, Seattle Children’s Hospital
—Merl Hoekstra, vice president of corporate and business development, ELITech Group
—Patricia Hoffman, administrative director for research, Puget Sound Blood Center
—Ryan Holcomb, project director, Myriad Pharmaceuticals
—Mark Honda, director of human resources, CMC Icos
—Shawn Hooper, sales manager, Charles River Laboratories
—Monique Howard, senior associate scientist, Amgen
—Yvonne Howard, purchasing agent, Boeing
—Scott Hussell, senior research associate, Novo Nordisk
—Sally Thompson Iritani, associate director, ZymoGenetics
—Christopher Irons, contract biotech drug researcher
—Irina Jacobson, associate director of research chemistry, AVI Biopharma
—Laury Jenkins, executive assistant, CMC Icos
—Bohan Stan Jin, scientist II, Takeda San Diego
—Bryan Jones, biotech and pharmaceutical consultant
—Padmaja Juwadi, director of quality assurance, Dr. Reddy’s Laboratories [Added at 5:30 Pacific, 3/10/10]
—Suzanne Kanaly, scientific director, pathology, Allergan
—Ramesh Kasar, scientist
—Adam Kashishian, staff scientist at Calistoga Pharmaceuticals
—Heather Kean, administrative assistant, Seattle Genetics
—Kathy Keegan, principal scientist, Amgen
—Gary Keizur, director of quality assurance/quality control, MediQuest Therapeutics
—Michael Kellogg, associate director of facilities and operations, Trubion Pharmaceuticals
—Ed Kesicki, director of small molecule drug discovery, Infectious Disease Research Institute
—Pat Kilgannon, former director of project management, ZymoGenetics
—Musong Kim, research scientist, Gilead Sciences
—Jonathan Klepinger, senior research associate, Trubion Pharmaceuticals … Next Page »
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Johnny T. Stine
11/18/09 1:48 pm
I actually loved our logo – very simple, but it just looked like fun.
When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.
By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)
Luke Timmerman
11/18/09 2:04 pm
Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.
I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?
David Miller
11/23/09 2:54 pm
Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.
Abby Kliphardt
3/3/10 10:19 am
Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….